ARTICLE | Clinical News
Foresee reports Phase I data for asthma/COPD candidate
January 5, 2018 9:56 PM UTC
Foresee Pharmaceuticals Co. Ltd. (TPEx-E:6576) reported data from a pair of double-blind Phase I trials in healthy volunteers showing that asthma and chronic obstructive pulmonary disease (COPD) candidate FP-025 was generally well tolerated with no serious adverse events reported.
The placebo-controlled trials evaluated single doses of up to 800 mg oral FP-025 in 64 subjects and multiple doses of up to 400 mg oral FP-025 in 24 subjects. An open-label portion evaluated single doses of 200 mg FP-025 with and without food in eight subject. The trials evaluated safety and pharmacokinetics...
BCIQ Company Profiles